With the United Nations High-Level Meeting (UNHLM) on TB just weeks away, the TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a special meeting on TB research and development (R&D) advocacy in the run up to this milestone event.

The new prices are valid through December 2024 and present price reductions up to 55% compared to the previous price of US$289 for a 6-month treatment course of bedaquiline.

A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London. Results have been published in NEJM Evidence.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

A comment, published in The Lancet Microbe, laid out key steps for expanding access to TB diagnostics to support the implementation of shorter, safer TB regimens demanded by the 1/4/6x24 Campaign.

A webinar, co-hosted by Stop TB Canada and Results Canada, provided an overview of the research & development (R&D) landscape for TB, including an assessment of how global TB R&D investments compare to the financial need identified in the new Global Plan to End TB.

The campaign calls for high-level participation in the 22 September meeting, and strong and ambitious commitments by all Heads of State and Governments.

NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

The World Health Organization’s 2023 Model Lists of Essential Medicines, published in July 2023, features key updates to the TB section.

A new study quantifies the substantial impact of diet on the successful treatment and containment of tuberculosis.